AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity01/09/2019
30M U.S. adults suffer from diabetes and 93M from obesity, with
associated medical costs of over
$300Bannually, necessitating an urgent need for novel treatments
- AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels found in young adults
- Loss of brown fat as a result of aging is associated with obesity and Type II diabetes as well as heightened cardiovascular risk
- Published data shows that AgeX’s pioneering PureStem® cell therapy manufacturing platform generated highly pure, identifiable and scalable brown adipose cells, expressing active adipokines such as adiponectin
As described in the paper, “Clonal Derivation of White and Brown Adipocyte Progenitor Cell Lines from Human Pluripotent Stem Cells,” two AgeX-BAT1 cell lines, designated NP88 and NP110, were selected for detailed characterization. The data demonstrate AgeX’s PureStem® cell therapy manufacturing platform was successful in generating highly purified cells with precise anatomical identity, and most importantly, capable of potently expressing definitive markers of BAT cells, including active adipokines such as adiponectin. Adiponectin is reported to have beneficial effects in patients with age-related metabolic and cardiovascular diseases. In addition, the paper provides evidence that AgeX’s PureStem® technology allows for the reliable re-derivation of scalable lots of desired cells.
“In keeping with AgeX’s mandate to use regenerative biology to reverse
the degenerative aspects of aging, AgeX-BAT1 will address one of the
insidious age-related metabolic imbalances responsible for age-related
weight gain as well as other serious age-related conditions such as Type
II diabetes and its ensuing cardiovascular risk,” said
"Few medical conditions are as prevalent as age-related metabolic
imbalances, which carry along with them serious risks, including
diabetes, cardiovascular disease, blindness, amputations, and cancer,”
Dr. West will discuss the paper as part of his presentation
at Biotech Showcase, being held concurrently with the 2019
Track: Yosemite-A (Ballroom Level)
Authors on the paper are
The paper is available online, and additional information on AgeX-BAT1, including an introductory video, is available on AgeX’s website at www.agexinc.com.
The activity of brown adipose tissue (BAT), or “brown fat”, is abundant early in life, but is lost precipitously with age. This tissue is believed to generate heat using blood glucose and circulating fat. The abundance of this tissue in the young is believed to keep metabolism in balance. Its loss with age is understood to lead to weight gain, central obesity, accumulation of fat in the coronary arteries, and Type II diabetes.
The demonstration that the transplantation of BAT from young mice to obese diabetic mice results in improvements in both weight and insulin sensitivity has led to a search for a source of industrially-scalable clinical grade BAT cells to recreate youthful levels of the tissue in old age.
AgeX plans to use HyStem® as a matrix to support the
engraftment of AgeX-BAT1 cells. HyStem® is a matrix
previously used in clinical trials by
For more information, please visit www.agexinc.com
or connect with the company on Twitter,
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005309/en/
Gotham Communications, LLC